Related Experiment Video
Updated: May 8, 2026
12:52
Iridium(III) Luminescent Probe for Detection of the Malarial Protein Biomarker Histidine Rich Protein-II
Published on: July 7, 2015
Mapping the protein-binding sites for novel iridium(III) anticancer complexes using electron capture dissociation
Rapid Communications in Mass Spectrometry : RCM
|August 14, 2013
Summary
Novel iridium (Ir) anticancer complexes bind to specific methionine sites on calmodulin, identified using electron capture dissociation (ECD) mass spectrometry. This differs from platinum (Pt) complexes and aids understanding of metallodrug mechanisms.
Area of Science:
- Biochemistry
- Mass Spectrometry
- Medicinal Chemistry
Background:
- Novel cyclopentadienyl iridium(III) complexes show promise as anticancer agents.
- Understanding their interaction with biological targets like calmodulin is crucial for drug development.
- Conventional mass spectrometry fragmentation methods (CAD, IRMPD) were insufficient to pinpoint iridium binding sites.
Purpose of the Study:
- To identify the specific binding sites of novel Ir(III) anticancer complexes on the calmodulin protein.
- To investigate the reaction mechanisms of these iridium complexes with calmodulin.
- To compare the binding and modification patterns with established platinum(II) anticancer drugs.
Main Methods:
- Utilized Fourier transform ion cyclotron (FT-ICR) tandem mass spectrometry.
- Employed a combination of top-down and bottom-up mass spectrometry approaches.
- Electron capture dissociation (ECD) was key for localizing iridium modifications on calmodulin.
Main Results:
- Ir(III) complexes preferentially bind to methionine residues within calmodulin.
- The efficiency of iridium modification on the protein is notably low compared to platinum complexes.
- Unlike platinum(II) complexes, iridium complexes did not induce protein crosslinking.
Conclusions:
- This study provides the first report on the interaction of novel Ir-based anticancer complexes with proteins.
- The findings offer valuable insights into the protein targets of this class of metallodrugs.
- Understanding these interactions aids in elucidating mechanisms of cancer cell growth inhibition and drug transport.
